Author + information
- Received May 22, 1984
- Revision received October 16, 1984
- Accepted November 5, 1984
- Published online March 1, 1985.
- Pierre Théroux, MD, FACC*,1,
- Yves Taeymans, MD1,
- Doris Morissette, RN1,
- Xavier Bosch, MD1,
- Guy B. Pelletier, MD, FACC1 and
- David D. Waters, MD, FACC1
- ↵*Address for reprints: Pierre Théroux, MD, Montreal Heart Institute, 5000 East Belanger Street, Montreal, Quebec HIT 1C8, Canada.
One hundred consecutive patients hospitalized in the coronary care unit for unstable angina, excluding patients with Prinzmetal's variant angina, were randomized within 24 hours of admission to treatment with diltiazem (50 patients) or propranolol (50 patients). Also excluded were patients with previous coronary artery bypass surgery and those receiving a beta-receptor blocking agent at the time of hospital admission. Left ventricular function and the extent of coronary artery disease were similar in the two groups.
During the hospital stay, the number of chest pain episodes decreased from a mean (± SD) of 0.75 ± 0.1 per patient per day to 0.26 ± 0.07 (p < 0.05) with diltiazem and 0.29 ± 0.1 (p < 0.05) with propranolol therapy. The circadian distribution of chest pain episodes was affected similarly. After 1 month, 14 of the patients treated with diltiazem were symptom-free compared with 13 treated with propranolol. At a mean follow-up time of 5.1 months (range 1 to 15), death had occurred in two patients in each group and myocardial infarction in five diltiazem- and four propranolol-treated patients (difference not significant). Coronary artery bypass surgery had been performed in 21 diltiazem-and 19 propranolol-treated patients (difference not significant). Only 15 patients were symptom-free, 9 treated with diltiazem and 6 with propranolol.
This similar result observed with the two forms of treatment suggests that coronary artery spasm may not be the main factor involved in unstable angina when Prinzmetal's variant angina is excluded. It also suggests that diltiazem can be used as an alternative to the usual treatment with beta-receptor blocking drugs.
- Received May 22, 1984.
- Revision received October 16, 1984.
- Accepted November 5, 1984.
- American College of Cardiology Foundation